Hepatocellular Carcinoma
Conditions
Interventions
Case series: DEB-TACE
Sponsors
The First Affiliated Hospital,College of Medicine,Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) aged 18-75 years male and female; 2) hepatocellular carcinoma was diagnosed by histopathological or clinical diagnosis (refer to the 2017 edition of the diagnostic and therapeutic guidelines for primary liver cancer); 3) unresectable advanced HCC; 4) the expected survival period is more than 3 months; 5) good liver function: child-pugh A or B (< = 7); 6) blood routine HB was greater than or equal to 90g/L;PLT greater than 50 x 109/L (no blood transfusion or drug therapy was corrected within 14 days before screening); 7) ECOG scores 0-2; 8) understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) patients with distant metastasis of tumor; 2) patients with obvious arteriovenous fistula;3) liver transplant recipients; 4) has suffered from or is currently developing other malignant tumors; Above level 5) ? myocardial ischemia and myocardial infarction, high blood pressure and the drug treatment can't will to normal range (contraction >140mmHg, diastolic >90mmHg); 6) patients with a history of gastrointestinal bleeding or obvious bleeding tendency within 6 months; 7) urine routine showed that urine protein was greater than ++ or 24-hour urinary protein quantification was confirmed; 8) pregnant or lactating women; 9) patients who have participated in other experimental drugs or instruments within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR+PR;TTP (time-to-progression); | — |
Countries
China
Contacts
Public ContactBao-quan Wang
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed